COMMONWEALTH OF AUSTRALIA
Department of Health
Therapeutic Goods Administration
THERAPEUTIC GOODS ACT 1989
Sections 14 and 14A Notice
On 9 December 2015, a delegate of the Secretary of the Department of Health, on the application of Biogen Australia Pty Ltd, consented under sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) to the supply of
- peginterferon beta-1a (rch) (PLEGRIDY) 63 microgram/0.5 mL and 94 microgram/0.5 mL solution for injection pre-filled pen TITRATION PACK [AUST R 214200]
- peginterferon beta-1a (rch)(PLEGRIDY) 125 microgram/0.5 mL solution for injection pre-filled pen [AUST R 214197]
- peginterferon beta-1a (rch)(PLEGRIDY) 63 microgram/0.5 mL and 94 microgram/0.5 mL solution for injection pre-filled syringe TITRATION PACK [AUST R 214198]
- peginterferon beta-1a (rch) (PLEGRIDY) 125 microgram/0.5 mL solution for injection pre-filled syringe [AUST R 214199]
that do not conform with the requirements of paragraph 3(2)(l)of the Therapeutic Goods Order No 69 – General requirements for labels for medicines, in that the sponsor’s old street address (for all batches given in Table 1) will be on the product labels until such time as labels with the revised sponsor address are approved by the Therapeutic Goods Administration and implemented in the supply chain.
Table 1: List of batches with sponsor’s old street address (Suite 1, Level 5, 123 Epping Road North Ryde) on the labels:
ARTG Number | Product | Batch Number(s)
|
214200 | peginterferon beta-1a (rch) (PLEGRIDY) 63 microgram/0.5 mL and 94 microgram/0.5 mL solution for injection pre-filled pen TITRATION PACK | 150445A 150565A 150396A 150642A |
214197 | peginterferon beta-1a (rch) (PLEGRIDY) 125 microgram/0.5 mL solution for injection pre-filled pen | 150564A 150783AS |
214198 | peginterferon beta-1a (rch) (PLEGRIDY) 63 microgram/0.5 mL and 94 microgram/0.5 mL solution for injection pre-filled syringe TITRATION PACK | 140839A |
214199 | peginterferon beta-1a (rch)( PLEGRIDY) 125 microgram/0.5 mL solution for injection pre-filled syringe | 140840A |
In addition to the above, you also asked for the Secretary’s consent to supply the products in Australia notwithstanding they do not conform with the requirements of the paragraph 3(2)(l)of the Therapeutic Goods Order No 69 – General requirements for labels for medicines in that sponsor’s old name ( for batches listed in Table 2) will be on the product labels to facilitate inventory management associated with the changes in both sponsor name and sponsor address.
Table 2: List of batches with sponsor’s old name (Biogen Idec Australia Pty Ltd) on the labels:
ARTG Number | Product | Batch Number(s)
|
214200 | peginterferon beta-1a (rch) (PLEGRIDY) 63 microgram/0.5 mL and 94 microgram/0.5 mL solution for injection pre-filled pen TITRATION PACK | 150445A 150565A 150396A 150642A
|
214197 | peginterferon beta-1a (rch) (PLEGRIDY) 125 microgram/0.5 mL solution for injection pre-filled pen | 150564A 150783AS
|
The consent is effective from 9 December 2015 until 24 June 2017.
The consent is subject to the following conditions:
- This consent applies to those batches (listed in Table 1) that are warehoused in Australia, those already produced, labelled and packed for Australia and held in overseas warehousing, or those currently in production for Australia.
- For batches of products listed in Tables 1 and 2 other sponsor’s valid contact information such as telephone and postal address details will remain the same.
- The new office location is clearly signposted within the building and postal communications are being received at the new office.
- The sponsor will submit changes to labels and product information for approval under section 9D of the Act to reflect the revised sponsor’s name and address.